Key Highlights

  • Convatec Group Plc (LSE:CTEC) rose 2.36%, adding 5p to close at 217p, ranking second among FTSE 100 risers on 29 September 2026.
  • The Interim Dividend of 2.166 US cents per share, up about 15%, is due to be paid on 30 September 2026.
  • A $200 million share buyback programme is running through to the end of 2026, providing steady support to the shares.
  • Management expects a materially stronger second half, led by faster growth in Infusion Care.
  • Defensive healthcare names attracted buyers as rising Global Bond yields and oil Volatility unsettled the wider market.

Convatec Among the Biggest FTSE 100 Gainers

Convatec Group Plc (LSE:CTEC) was one of the best performing stocks in London on Tuesday, 29 September 2026, rising 2.36% to 217p, a gain of 5p on the day. The medical products and technologies company, which specialises in chronic care across advanced wound care, ostomy care, continence care and infusion care, finished as the second strongest riser on the FTSE 100.

The move came on a day when the Blue-Chip index fell 0.45%, pressured by soaring US bond yields and weaker energy stocks. Against that uncertain backdrop, investors gravitated toward defensive names with steady, Recurring Revenue streams, and LSE:CTEC fitted that profile well.

Key Reasons Why Convatec Shares Moved Up

The first reason was the approaching dividend payment. Convatec's interim dividend of 2.166 US cents per share, an increase of about 15% on last year, is scheduled to be paid on 30 September 2026. While the shares went ex-dividend in August, the payment date often brings the income appeal of the stock back into focus, and the double-digit dividend increase signals management confidence.

The second driver was the ongoing $200 million share buyback. The company is steadily repurchasing shares through to the end of 2026, which reduces the share count and supports Earnings Per Share growth. Buybacks also provide consistent Demand for the stock, particularly on days when broader markets are weak.

The third Factor was the defensive rotation across the market. With the US 30-year Treasury Yield hitting its highest level since 2002 and Brent Crude swinging on Middle East headlines, many fund managers sought shelter in healthcare stocks whose demand is less tied to the economic cycle.

Second-Half Acceleration in Focus

Convatec narrowed its 2026 organic revenue growth guidance, excluding InnovaMatrix, to 5.5% to 6.5% when it reported interim results in August. Management expects organic growth of 6% to 8% in the second half, led by an acceleration in Infusion Care where demand for both diabetes and non-diabetes therapies, including a Parkinson's treatment partnership, is strong.

First-half revenue rose 4.4% to $1.23 billion, while adjusted operating profit climbed 3.9% to $262 million. The adjusted Operating Margin stood at 21.2%, but the company expects the second-half margin to be materially higher, keeping it on track for a full-year margin of at least 23%. Adjusted Diluted Earnings per Share rose 6.3% to 8.5 cents, and the group continues to target double-digit adjusted earnings growth for the year.

The main drag has been InnovaMatrix, a wound care product hit by sharp cuts to US Medicare reimbursement for skin substitutes. Revenue from that product collapsed in the first half and triggered a $69 million impairment. However, investors increasingly see this headwind as largely behind the company, allowing the stronger core Business to shine.

Why LSE:CTEC Is in Focus for Investors

Convatec is attracting attention because it is executing on its Accelerate strategy under Chief Executive Jonny Mason, who took the helm late last year. The strategy aims to improve execution, bring innovative chronic care products to more patients and lift the operating margin into the mid-twenties by 2027. From 2027, the company targets organic revenue growth of 6% to 8% a year with double-digit earnings growth.

Investors are watching the next trading update closely for confirmation that the second-half acceleration is on track. Other points of focus include US reimbursement developments, the pace of new product launches such as the Esteem Body ostomy range, which has reached annualised revenue of around $60 million, and the progress of GentleCath Air for Women in continence care.

Investor Sentiment and Social Media Trends

On investor forums and social media, Convatec discussion focused on the stock's resilience, its rising dividend and the continuing buyback, with many retail investors viewing the current level as attractive.

Outlook for Convatec Shares

Convatec Group Plc (LSE:CTEC) enters the final quarter of 2026 with a clear roadmap: stronger second-half growth, expanding margins and cash returns to shareholders. Risks include further US reimbursement changes, currency swings given its dollar reporting and execution risk around new launches. Still, Tuesday's gain shows investors are increasingly willing to back the company's recovery narrative, especially as markets search for dependable defensive growth.